Enabling Autoantibody Quantification through xMAP Multiplexing Technology with Live Q&A

Описание: Presented By: Petra Budde, PhD

Speaker Biography: Petra is the Chief Scientific Officer at Oncimmune Germany GmbH, a position she has held since 2023. Petra led the Medical Research department of Protagen AG from 2012 and on the acquisition of Protagen AG by Oncimmune in 2019 Petra assumed the role of Director of Medical Research. Prior to joining Oncimmune, she held senior management positions at Proteome Sciences (Frankfurt, Germany) and Digilab BioVisioN (Hanover, Germany), where she led autoimmune disease, diabetes, and oncology biomarker development programmes. In her previous roles, Petra worked for biomarker discovery companies specializing in proteomics and gained extensive experience in omics-type biomarker programmes, collaborating with pharma, biotech, and academic partners to address the need for biomarkers throughout all phases of clinical drug development. Throughout her career, she has specialised in B cell-mediated immunity, antigen presentation, autoimmunity, and allergy. She received her PhD (Dr. rer. nat.) from the University of Bielefeld (Germany) and was a Postdoctoral Fellow at the Laboratory of Molecular Biology (LMB) in Cambridge, UK.

Webinar: Enabling Autoantibody Quantification through xMAP Multiplexing Technology with Live Q&A

Webinar Abstract: Emerging therapeutic strategies for autoantibody-mediated diseases increasingly prioritise the selective reduction of pathogenic autoantibodies over global immune suppression, positioning autoantibodies as key mechanism of action (MoA) biomarkers in clinical trials. Autoimmune disorders such as systemic lupus erythematosus (SLE) and Sjögren’s disease (SjD) are characterised by the presence of multiple high-titre autoantibodies, necessitating robust multiplex quantification methods to enable precise and cost-effective monitoring of treatment-induced changes. This presentation introduces (semi)quantitative methodologies, including cut-point calibration using cohort-based reactivity thresholds, dilution curve analyses to determine autoantibody titres, alongside the integration of inline calibration using reference materials within the Luminex IntelliFlex DR system. The dual-reporter functionality of the IntelliFlex DR platform enables assay calibration by enabling concurrent detection of autoantibodies and internal calibration controls within a single measurement, thereby improving data accuracy and reproducibility. These advancements facilitate precise autoantibody quantification, supporting patient stratification based on distinct serological profiles and enabling the identification of disease subgroups with unique clinical phenotypes or differential treatment responses. The incorporation of internal calibration materials represents a significant advancement in multiplex quantification, reinforcing the utility of the IntelliFlex DR system for MoA biomarker analysis in clinical studies.

Labroots on Social:
Facebook:   / labrootsinc  
Twitter:   / labroots  
LinkedIn:   / labroots  
Instagram:   / labrootsinc  
Pinterest:   / labroots  
SnapChat: labroots_inc